Alzheimer's disease neprilysin gene therapyAlternative Names: Alzheimer's disease gene therapy; Lenti-Nep
Latest Information Update: 11 Dec 2007
At a glance
- Originator Salk Institute; University of California, San Diego; University of Kentucky
- Class Antidementias; Gene therapies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease